Exceptional response to immunotherapy monotherapy in a patient with an unfavorable subset of cancer of unknown primary

被引：0
作者：
Huang, Xiangzhong [1 ]
Ren, Dongqing [1 ]
Sun, Qiulian [2 ]
Xu, Xinjian [1 ,3 ]
Ding, Yiwen [1 ,3 ]
机构：
[1] Nantong Univ, Jiangyin Hosp Affiliated, Dept Intervent Radiol, Jiangyin, Peoples R China
[2] Fifth Peoples Hosp Suzhou, Dept Radiol, Suzhou, Peoples R China
[3] Nantong Univ, Jiangyin Hosp Affiliated, Dept Intervent Radiol, 3 Yingrui Rd, Jiangyin 214400, Peoples R China
来源：
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY | 2023年 / 13卷 / 12期
关键词：
D O I：
10.21037/qims-23-284
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：8832 / 8838
页数：7
相关论文
共 18 条
[1]   Melanoma of unknown primary: New perspectives for an old story [J].
Boussios, Stergios ;
Rassy, Elie ;
Samartzis, Eleftherios ;
Moschetta, Michele ;
Sheriff, Matin ;
Alejandro Perez-Fidalgo, Jose ;
Pavlidis, Nicholas .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 158
[2]   Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].
Chan, T. A. ;
Yarchoan, M. ;
Jaffee, E. ;
Swanton, C. ;
Quezada, S. A. ;
Stenzinger, A. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56
[3]   Chromosomal instability in cancers of unknown primary [J].
Chebly, Alain ;
Yammine, Tony ;
Boussios, Stergios ;
Pavlidis, Nicholas ;
Rassy, Elie .
EUROPEAN JOURNAL OF CANCER, 2022, 172 :323-325
[4]   Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site [J].
Culine, S ;
Kramar, A ;
Saghatchian, M ;
Bugat, R ;
Lesimple, T ;
Lortholary, A ;
Merrouche, Y ;
Laplanche, A ;
Fizazi, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4679-4683
[5]   Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial [J].
Hayashi, Hidetoshi ;
Takiguchi, Yuichi ;
Minami, Hironobu ;
Akiyoshi, Kohei ;
Segawa, Yoshihiko ;
Ueda, Hiroki ;
Iwamoto, Yasuo ;
Kondoh, Chihiro ;
Matsumoto, Koji ;
Takahashi, Shin ;
Yasui, Hisateru ;
Sawa, Toshiyuki ;
Onozawa, Yusuke ;
Chiba, Yasutaka ;
Togashi, Yosuke ;
Fujita, Yoshihiko ;
Sakai, Kazuko ;
Tomida, Shuta ;
Nishio, Kazuto ;
Nakagawa, Kazuhiko .
JAMA ONCOLOGY, 2020, 6 (12) :1931-1938
[6]   Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis [J].
Khunger, Monica ;
Hernandez, Adrian V. ;
Pasupuleti, Vinay ;
Rakshit, Sagar ;
Pennell, Nathan A. ;
Stevenson, James ;
Mukhopadhyay, Sanjay ;
Schalper, Kurt ;
Velcheti, Vamsidhar .
JCO PRECISION ONCOLOGY, 2017, 1 :1-15
[7]   SEOM clinical guideline on unknown primary cancer (2017) [J].
Losa, F. ;
Soler, G. ;
Casado, A. ;
Estival, A. ;
Fernandez, I. ;
Gimenez, S. ;
Longo, F. ;
Pazo-Cid, R. ;
Salgado, J. ;
Segui, M. A. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (01) :89-96
[8]   Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary [J].
Mei, Jie ;
Wang, Hao ;
Fan, Honghong ;
Ding, Junli ;
Xu, Junying .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[9]   Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary [J].
Moran, Sebastian ;
Martinez-Cardus, Anna ;
Boussios, Stergios ;
Esteller, Manel .
NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (11) :682-694
[10]   Cancer of unknown primary site [J].
Pavlidis, Nicholas ;
Pentheroudakis, George .
LANCET, 2012, 379 (9824) :1428-1435
12